AstraZeneca Teams with Daiichi Sankyo to Speed Development of HER2-positive Advanced Breast Cancer Therapy

AstraZeneca Teams with Daiichi Sankyo to Speed Development of HER2-positive Advanced Breast Cancer Therapy

AstraZeneca is starting a collaboration with Daiichi Sankyo for the global production and commercialization of trastuzumab deruxtecan (DS-8201), a novel antibody-drug conjugate under clinical studies for the treatment of advanced HER2-positive breast cancer, and other types of solid tumors.

The investigational therapy was granted fast track status by the U.S. Food and Drug Administration (FDA) in 2016, and gained breakthrough therapy designation in 2017, for patients with HER2-positive, locally advanced or metastatic breast cancers that progressed after prior HER2 therapies, including Kadcyla (ado-trastuzumab emtansine).
Early results from a pivotal Phase 1 clinical trial (NCT02564900), still  underway, show that treatment with trastuzumab deruxtecan has a "strong activity in a number of tumor types," Astrazeneca stated in a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.